PARIMATCH
Sergey Portnov, CEO of Parimatch, took to the virtual stage yesterday at Collision at Home – a global virtual conference which brings together tech leaders and high-potential start-ups to discuss the issues affecting the tech industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200626005045/en/
During his speech, Sergey Portnov captivated Collison at Home’s 30,000 strong audience with his experience of transforming Parimatch from a physical bookmaker into a leading international tech and entertainment brand, giving viewers his top five tips on tech transformation.
On transforming into a tech business, Sergey Portnov said:
“At Parimatch we are obsessed with technology. We are a business built by businesspeople with management backgrounds, but now we have taken a major step to becoming a tech business – an endless journey with no destination.
“Tech can either be used as a tool, or can be used to describe a culture, a mindset. Previously at Parimatch, we used tech as a tool, but not anymore. Tech isn’t something which can be outsourced, it has to flow through your DNA. Only once you have this tech culture ingrained in your business will your company start to move ahead.”
Sergey’s top five tips on tech transformation:
Lesson 1 – Accept the sacrifice
“In the journey to tech transformation, you need to accept that you will lose things along the way. You may lose employees, customers, partners, maybe even revenue. Whilst this can be painful, this loss has to be accepted in order to transform and ultimately become stronger.”
Lesson 2 – Hire the best
“Don’t take the easy approach when it comes to hiring talent. We all know that it is people who make (or break) a business. Invest in the best people, and pay them a lot. People should be a serious financial investment. But don’t just pay them well, give them freedom in their role. Motivate them, and give them time to shine.”
Lesson 3 – Speed is of the essence
“For me, tech means speed. Every aspect of a tech business needs to be working at speed. The sports and betting industry are very fast paced, so we are able to surround our brand with that speedy energy. Be audacious and brave, create a culture of speed.”
Lesson 4 – Build company culture
“We are continually working on how to foster loyalty from our existing employees. We work with all of our people and spend time building culture and values. These aren’t just words on paper, we live them and people can see them in our actions. Values need to be authentic, and are essential to building a positive culture, and need to form the backbone of a business.”
Lesson 5 – Balance experience with ambition
“It is important to balance experience with ambition. When one outweighs the other, it causes problems. We were ambitious with little experience once upon a time, we made mistakes and learnt from them. On the other hand, you have businesses with lots of experience but no ambition, they have become complacent and are not likely to last into the future. The ideal balance is 51% ambition and 49% experience.”
A recording of Sergey Portnov’s speech can be viewed here: https://www.youtube.com/watch?v=CQ98g1U-doU&feature=youtu.be
-ENDS-
ABOUT PARIMATCH
Parimatch brings together technology, business and sport to deliver seamless entertainment powered by innovation. Founded in 1994, Parimatch has grown to become one of the largest betting companies in Europe and the CIS, and continues to explore new markets to enter. The business operates with a digital first mindset, and is constantly developing and improving the quality of its customer experience, which is enjoyed in 60 countries across the world. Parimatch’s winning team of brand ambassadors include Conor McGregor, Mike Tyson, Petr Yan and the Shevchenko sisters. Parimatch is also the title sponsor of the popular esports team Virtus.pro, and is the exclusive betting partner to UFC in the CIS region.
ABOUT COLLISION
Collision is “America’s fastest growing tech conference” created by the team behind Web Summit. In five years, Collision has grown from 2,500 to an expected 25,000 attendees from more than 120 countries. Attendees include CEOs of both the world’s fastest growing startups and the world’s largest companies, alongside leading investors and media.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200626005045/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
